|
| Press Releases |
|
 |
|
| Tuesday, December 1, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Monday, November 30, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Wednesday, November 11, 2020 |
|
|
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. more info >> |
|
| Monday, November 2, 2020 |
|
|
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity |
| BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
天數智芯通用GPU收入同比增長149.6% 推理系列大增238.2%
Apr 2, 2026 16:38 HKT/SGT
|
|
|
天数智芯通用GPU收入同比增长149.6% 推理系列大增238.2%
Apr 2, 2026 16:34 HKT/SGT
|
|
|
把握IPO回暖機遇 聯想控股戰略轉型邏輯逐步兌現
Apr 2, 2026 16:23 HKT/SGT
|
|
|
把握IPO回暖机遇 联想控股战略转型逻辑逐步兑现
Apr 2, 2026 16:17 HKT/SGT
|
|
|
JRC, SKY Perfect JSAT, and Sharp Collaborate to Promote the Ministry of Defense's Publicly Announced Project "Development and Demonstration of Resiliency Technology for Multi-Orbit Communications Systems" Selected for JRC
Apr 2, 2026 16:01 JST
|
|
|
MHIEC、「県央県南広域環境組合南部リレーセンター建設工事」を完工
Apr 2, 2026 15:00: JST
|
|
|
TOYOTA、米国生産のタンドラ、ハイランダーを発売
Apr 2, 2026 15:00: JST
|
|
|
MHIEC Completes Construction of Nanbu Relay Center for Nagasaki Prefecture's Ken'ou-Kennan Clean Authority
Apr 2, 2026 14:57 JST
|
|
|
Dialogue with HighTide Therapeutics' CMO Dr. Filip Surmont: Moving Beyond the "Blockbuster" Legacy to Reshape Kidney Disease Treatment Through a Dual-Mechanism Approach
Apr 2, 2026 12:00: JST
|
|
|
Dialogue with HighTide Therapeutics' CMO Dr. Filip Surmont: Moving Beyond the "Blockbuster" Legacy to Reshape Kidney Disease Treatment Through a Dual-Mechanism Approach
Apr 2, 2026 11:00 HKT/SGT
|
|
|
Mazda EZ-6/Mazda6e Wins 2026 World Car Design of the Year Award
Apr 2, 2026 11:47 JST
|
|
|
TransNusa Strengthens Domestic Network Connection with New Route Launch and Increased Scheduled Flight Frequency
Apr 2, 2026 10:14 HKT/SGT
|
|
|
RMB 2 Billion Investment Leverages Approximately RMB 8 Billion in Book Value Gains: Shoucheng Holdings (0697.HK) Enters the Monetization Phase of Its Robotics Investments
Apr 2, 2026 08:30 HKT/SGT
|
|
|
20億元布局撬動約80億元賬面增值 首程控股（0697.HK）機器人投資進入兌現窗口
Apr 2, 2026 08:30 HKT/SGT
|
|
|
Datavault AI Inc.（納斯達克代碼：DVLT）與 Demora Foundation 簽署技術整合協議，共同打造韓流娛樂與全球平台
Apr 2, 2026 06:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
